The Revolution of Obesity Treatment: A $100 Billion Market in the Making

More than 1 billion people worldwide live with obesity today. Once dismissed as a failure of willpower, obesity is now recognized by the world's leading medical bodies as a complex, multifactorial chronic disease, one that silently fuels a cascade of life-threatening conditions, including type 2 diabetes, cardiovascular disease, sleep apnea, fatty liver disease, and certain cancers.

With obesity linked to severe health conditions and certain cancers, the need for effective interventions is expanding rapidly. The total prevalent cases of obesity are expected to rise from ~194 million in 2025 to ~228 million by 2036 across the leading markets (the US, EU4, the UK, and Japan), as per DelveInsight.

For decades, treatment options were limited to lifestyle changes, behavioral therapy, and bariatric surgery, tools that were either insufficient or inaccessible for the majority of patients. Then came the GLP-1 revolution. And the obesity treatment market has never looked the same since.

Today, the obesity drug market is on a meteoric trajectory, projected to surpass USD 80 billion by 2034, with DelveInsight’s analysts placing it closer to USD 100 billion by 2036. Behind this explosion lies a perfect storm of surging disease prevalence, paradigm-shifting drug approvals, and a fierce pharmaceutical rivalry that is rewriting the future of cardiometabolic medicine.

Obesity and Its Web of Comorbidities: Why the Stakes Are So High

To understand the scale of the obesity treatment market, one must first understand obesity's role as the cornerstone of modern medicine. Obesity is associated with more than 200 complications. The most consequential include:

Type 2 Diabetes (T2DM): Obesity significantly elevates the risk of developing diabetes, and the two conditions are so intertwined that the term "diabesity" has entered clinical parlance. Today, approximately 589 million adults (aged 20–79) are living with diabetes globally, over 90% of whom have T2DM, representing 11.1% or 1 in 9 of the adult population. In the United States alone, an estimated 40.1 million people have diagnosed or undiagnosed diabetes as of 2023. Since type 2 diabetes represents the overwhelming majority of cases, the global type 2 diabetes population by 2036 is expected to exceed 700 million patients worldwide, as per DelveInsight.

Cardiovascular Disease (CVD): Cardiovascular diseases remain the leading cause of premature mortality in people with obesity. The mechanisms are both direct and indirect. Obesity elevates blood pressure, disrupts lipid metabolism, and promotes a chronic pro-inflammatory, prothrombotic state that accelerates atherosclerosis and increases risks for heart failure, atrial fibrillation, and myocardial infarction. For every 5-unit increment in BMI, the risk of coronary artery disease increases by approximately 30%. CVD currently claims an estimated 17.9 million lives per year globally, with deaths surging from 12.1 million in 1990 to 20.5 million in 2021, a 60% increase over three decades. In the U.S., 919K people died from cardiovascular disease in 2023 alone, equivalent to one death every 34 seconds. From 2020 to 2030, the global CVD burden is projected to continue rising.

Obstructive Sleep Apnea (OSA): Fat deposits in the upper airway and chest wall reduce respiratory efficiency during sleep, making obesity one of the strongest risk factors for OSA. In a landmark move, the FDA approved WEGOVY for OSA in adults with obesity in 2024, marking one of the most significant label expansions in recent memory. Current estimates put the global OSA burden at 936 million adults (aged 30–69) with mild-to-severe OSA, and 425 million with moderate-to-severe OSA, figures nearly 10 times higher than prior WHO estimates. As per DelveInsight, within the 7MM, the US accounted for the highest number of diagnosed OSA cases, estimated at around 14 million in 2024, with this figure expected to rise to 20 million by 2034.

Metabolically Dysfunctional-Associated Steatohepatitis (MASH)/MASLD: Visceral fat promotes hepatic lipid accumulation and inflammation, putting obese individuals at high risk of progressive liver disease. With Resmetirom (REZDIFFRA) approved for MASH in 2024, the crossover between obesity and liver disease treatments is becoming a major commercial frontier. Currently, 38% of all adults are estimated to have MASLD, and among patients with T2DM, the co-prevalence of MASLD is as high as 65–69%. Among the 7MM, the US had the highest number of diagnosed prevalent MASH cases, with ~5 million cases in 2025, a figure projected to reach 12 million by 2036.

Cancer: Obesity contributes to approximately 20% of all cancers, including endometrial, colorectal, breast, kidney, and esophageal cancers, a fact that adds both urgency and enormous long-term market potential to effective obesity treatment.

Mental Health Comorbidities: Weight stigma, social isolation, and hormonal dysregulation associated with obesity contribute significantly to depression, anxiety, and reduced quality of life, conditions that further diminish treatment adherence in a vicious cycle.

This constellation of comorbidities means that treating obesity is not merely cosmetic; it is a cardiovascular, metabolic, hepatic, oncological, and psychological intervention rolled into one. That breadth of impact is precisely what has ignited the current pharmaceutical gold rush.

The Evolution of GLP-1 Therapies in Obesity Management

No single scientific concept has done more to transform obesity treatment than the glucagon-like peptide-1 (GLP-1) receptor agonist mechanism. GLP-1 is an incretin hormone naturally secreted by intestinal L-cells in response to food intake. It performs several critical metabolic functions: stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and, crucially, signaling satiety to the hypothalamus.

Unlike older weight-loss drugs that bluntly suppress appetite through stimulant pathways, GLP-1 receptor agonists work with the body's own biology. GLP-1 receptors are scattered throughout the body, in the brain's hypothalamus, the gut, the pancreas, and even the heart, giving these drugs a remarkably broad therapeutic reach. By mimicking GLP-1 and extending its action far beyond the hormone's natural few-minute lifespan, drugs like WEGOVY and ZEPBOUND produce consistent, sustained reductions in caloric intake and significant body weight loss. Clinical trials have shown average weight reductions of 15–16% of body weight, numbers that were once only achievable through bariatric surgery.

For years, the biggest barrier to GLP-1 therapy was the needle. Injections, whether weekly or daily, limited patient acceptance, particularly in populations with needle anxiety or limited healthcare access. That barrier began to fall in December 2025, when the FDA approved the WEGOVY pill (oral semaglutide 25 mg), making it the first oral GLP-1 receptor agonist approved specifically for weight management. Participants in its pivotal 64-week Phase 3 trial lost an average of 14–16.6% of their body weight, a result on par with the injectable formulation, a landmark moment for obesity pharmacotherapy.

The oral GLP-1 revolution didn't stop with semaglutide. In April 2026, Eli Lilly's orforglipron (FOUNDAYO) secured FDA approval, becoming the first small-molecule GLP-1 receptor agonist approved for weight loss. Unlike peptide-based drugs such as semaglutide, which require complex formulation to survive stomach acid, small-molecule agonists are inherently more stable and easier to manufacture at scale. This distinction could be a game-changer for global access and affordability, potentially opening GLP-1 therapy to millions of patients in lower-income markets who previously couldn't access or afford injectable biologics.

The significance of these approvals extends far beyond weight numbers on a chart. GLP-1-based therapies are now demonstrating reductions in cardiovascular mortality, kidney disease progression, and even MASH, conditions that frequently accompany obesity.

The Giants' Duel: Novo Nordisk vs. Eli Lilly

No story in modern pharma captures the drama of innovation and competition quite like the Novo Nordisk vs. Eli Lilly rivalry in the obesity drug market. Novo effectively created the modern anti-obesity drug market. With WEGOVY generating USD 8 billion in US sales in 2025 alone, the Danish giant built enormous brand recognition and physician trust.

Momentum continued across launches and label expansions. By the end of 2025, WEGOVY had almost doubled its global footprint to reach 52 countries, with further roll‑outs planned in 2026, subject to local regulatory approvals. In the US, the label was expanded to include treatment of adults with MASH with moderate to advanced liver fibrosis, an important milestone given the high overlap between obesity and metabolic liver disease.

On the other hand, Lilly entered the obesity market later but moved with clinical precision. It's tirzepatide, a dual GIP/GLP-1 agonist, demonstrated clear superiority over semaglutide in a landmark head-to-head trial: patients on ZEPBOUND lost an average of 50 pounds over 72 weeks, compared to 33 pounds for those on WEGOVY, a result that significantly shifted prescriber and patient preference. In 2025 alone, US ZEPBOUND revenue reached USD 13.4 billion.

In summary, Novo Nordisk held the early advantage, but Eli Lilly began taking U.S. market share as early as June 2024. By February 2025, Lilly had taken the lead, and by early 2026, the company held approximately 60% of the U.S. GLP-1 obesity market. Lilly also guided above consensus expectations for 2026, while Novo warned of sales declines of 5–13% due to U.S. price pressures and international patent expirations.

As per Sadaf Javed, an endocrinology and metabolic disorders expert at DelveInsight, we view Lilly as the dominant player going forward, underpinned by the superior efficacy of tirzepatide, longer patent protection extending into "the back half of the 2030s," and an early foray into direct-to-consumer sales.

Yet the story is far from over. Novo is fighting back with a formidable next-generation portfolio.

The Emerging Pipeline in the Obesity Therapeutic Space

The current blockbusters are only the opening act. The obesity drug pipeline is among the most vibrant in all of medicine, with over 100 candidates across various stages of development targeting multiple physiological pathways.

Novo Nordisk's CagriSema

CagriSema is a once-weekly fixed-dose combination of cagrilintide (an amylin analog) and semaglutide (GLP-1). By combining two complementary mechanisms, GLP-1's appetite suppression and amylin's effect on satiety signaling and energy balance, CagriSema demonstrated greater weight loss than semaglutide alone. Novo Nordisk filed for FDA approval in 2025, making it the first-ever combination of GLP-1 and amylin analog to seek regulatory clearance for weight management. A formal approval decision is expected by late 2026, paving the way for a potential commercial launch either in late 2026 or early 2027.

If approved, CagriSema will directly compete with Eli Lilly's tirzepatide (ZEPBOUND) and the broader GLP-1 class, including standalone semaglutide (WEGOVY). Its dual-mechanism approach offers a potential edge, clinical trials have shown superior weight reduction compared to semaglutide alone, which could position it as a stronger option for patients who have plateaued on existing GLP-1 therapies. Additionally, the fixed-dose single-injection convenience may improve adherence over combination regimens that require separate administrations.

Pfizer's PF-07976016

Pfizer was initially viewed as one of the strongest contenders in the oral GLP-1 market. Its small-molecule therapy, danuglipron, delivered encouraging results in Phase 2b studies, achieving placebo-adjusted weight loss of nearly 8–13%. However, the program faced significant setbacks on the road to commercialization. More than half of participants discontinued treatment across dose groups due to gastrointestinal adverse events, while early studies also raised concerns related to liver safety. These challenges ultimately prompted Pfizer to halt the development of danuglipron in April 2025. Despite this setback, the company remains committed to the obesity space through the continued advancement of its oral GIPR antagonist candidate, PF-07976016, currently in Phase 2 development, alongside other early-stage obesity programs.

Eli Lilly’s Retatrutide

Eli Lilly's injectable retatrutide targets not just GLP-1 and GIP (as tirzepatide does), but also adds glucagon receptor agonism, creating a triple-action incretin effect. By adding glucagon receptor activation to the dual-agonist formula, retatrutide achieved up to 24% median weight loss in Phase 2 trials, with some patients losing over 71 pounds. It has advanced to Phase 3 and represents potentially the most powerful pharmacological weight loss tool ever developed. Tirzepatide's patent protection into the 2030s and retatrutide's early promise make Lilly's pipeline exceptionally robust. Eli Lilly and Company anticipates that the drug could reach the market between 2027 and 2028, subject to favorable clinical trial outcomes and regulatory clearance.

Upon approval, retatrutide will directly challenge Novo Nordisk's semaglutide (WEGOVY/OZEMPIC) and Lilly's own tirzepatide (MOUNJARO/ZEPBOUND), currently the dominant GLP-1 therapies, as well as next-generation pipeline entrants such as Novo Nordisk's CagriSema and survodutide. Its key differentiator lies in the added glucagon receptor agonism, which not only drives superior absolute weight reduction (approximately –16.3 kg vs. –11.8 kg for tirzepatide) but also delivers significantly greater liver fat reduction, making it a compelling option for patients with MASLD. However, retatrutide's higher adverse event profile compared to current standards may require careful patient selection and risk stratification to maximize its therapeutic benefit.

Boehringer Ingelheim’s Survodutide

Boehringer Ingelheim is developing BI 456906, a dual GLP-1/glucagon receptor agonist for obesity, overweight, and Metabolic dysfunction-associated steatohepatitis. Based on oxyntomodulin, it is designed to regulate metabolism through dual receptor activation in patients with BMI ≥27 and related metabolic conditions. The therapy is currently in Phase III clinical development within the company’s cardiometabolic pipeline. Boehringer Ingelheim expects to launch survodutide in 2027 or 2028, subject to the successful completion of its ongoing Phase III clinical trials.

Once approved, survodutide will directly compete with established GLP-1 receptor agonists such as semaglutide (WEGOVY/OZEMPIC) and tirzepatide (MOUNJARO/ZEPBOUND), as well as emerging dual and triple agonists in the pipeline. Its key differentiator lies in the added glucagon receptor activation, which may offer superior fat-burning and liver-targeted metabolic benefits, particularly relevant in MASH, an indication where pure GLP-1 agents have shown limited efficacy. This dual mechanism could position survodutide as a preferred option for patients with overlapping obesity and liver disease, carving out a distinct niche in an increasingly competitive cardiometabolic landscape.

Regor Therapeutics’ RGT-075

RGT-075 is a once-daily, orally administered small-molecule GLP-1 receptor full agonist developed by Regor for the treatment of metabolic disorders, including type 2 diabetes mellitus, obesity, and overweight conditions associated with weight-related comorbidities. The company has previously completed Phase IIa trials in obese patients, along with Phase I single ascending dose (SAD) studies in healthy volunteers and multiple ascending dose (MAD) studies in patients with diabetes. Clinical findings to date indicate that RGT-075 has demonstrated a favorable safety and tolerability profile, with early efficacy results showing potential comparable to approved peptide-based GLP-1 therapies.

Novo Nordisk’s Amycretin

Amycretin is gaining attention as a next-generation therapy in the obesity and type 2 diabetes space. Developed by Novo Nordisk, amycretin is a novel long-acting unimolecular agonist that targets both GLP-1 and amylin receptors and is being developed in both oral and subcutaneous formulations. By combining the glucose-regulating effects of GLP-1 with the appetite-suppressing and gastric-emptying properties of amylin, amycretin has the potential to deliver significant weight reduction along with meaningful metabolic improvements. Amycretin could be Novo's counter-punch to Lilly's oral ambitions.

Conclusion: A Medical Revolution in Real Time

The obesity treatment market is undergoing a transformation that can only be described as revolutionary. In less than a decade, a condition that was chronically undertreated and heavily stigmatized has become the defining therapeutic battleground of 21st-century medicine.

GLP-1 receptor agonists have crossed a threshold that few therapies ever do; they don't just treat a disease, they reframe it. By achieving weight loss that rivals surgery, reducing cardiovascular events, treating sleep apnea, and demonstrating benefits across a web of comorbidities, these agents are proving that obesity is a metabolic, neurobiological disease that responds to targeted pharmacological intervention.

The rivalry between Novo Nordisk and Eli Lilly will drive innovation for years to come. The emerging pipeline, from triple agonists and oral small molecules to amylin combinations and non-incretin mechanisms, promises even greater efficacy and broader access. And the macro tailwinds of surging disease prevalence, expanding indications, and improved access have set the stage for one of the most explosive market growth stories in modern pharmaceutical history.

The revolution is here. The question is no longer whether obesity can be treated, but how transformatively, for how many people, and at what cost.

Source: Obesity Clinical Trial Analysis

Obesity Pipeline report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key obesity companies, including Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.

Related Reports

GLP Agonists Clinical Trial Analysis

GLP Agonists Pipeline report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GLP agonists companies, including Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, Amgen, Viking Therapeutics, Regor Therapeutics, Carmot Therapeutics, Roche, GlaxoSmithKline, Sanofi, and others.

Metabolic Dysfunction-Associated Steatohepatitis Market

Metabolic Dysfunction-Associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MASH companies including Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Inc., Akero Therapeutics, Inc., 89bio, Inc., Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics Inc., Lipocine Inc., Viking Therapeutics, Inc., Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Inc., Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai) Co., Ltd., Hepion Pharmaceuticals, Inc., Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences Inc., Ionis Pharmaceuticals, Corcept Therapeutics, and others.

Diabetes Clinical Trial Analysis

Diabetes Pipeline report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetes companies, including vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc., and others.

Alzheimer's Disease Market

Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies including AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol Myers Squibb, Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA, Johnson & Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC, and others.